Fiche société
National Institute on Aging (NIA)
Traitements, essais et publications liés.
Traitements13programmes
Essais9liés
Publications28liées
SourceDBlocale
Traitements
13| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| Amyloid PET Imaging in the Baltimore Longitudinal Study of AgingBackground: Some people experience cognitive decline as they age. That is, they lose memory, problem-solving, and other mental abilities. Amyloids are groups of proteins that develop in the brain and increase in number as people age. Researchers want to use imaging scans to track amyloids in people s brains over time. Their goal is to find out if any changes are related to cognitive decline or other medical issues. Objective: To learn how amyloids may affect brain structure and function as people age. Eligibility: People aged 55 years and older who are enrolled in the Baltimore Longitudinal Study of Aging. Design: Participants will have imaging scans and other tests every 1 to 4 years, depending on their age. Those 80 and older will be scanned yearly. These scans will be done during regular BLSA visits. The scans will be positron emission tomography and computed tomography (PET CT). Participants will be given fluid through a tube inserted into a vein in their arm. The fluid is a tracer that will cause the amyloids to light up in the images. Then they will lie on a bed with their head inside a PET CT scanner. They will lie still for about 30 minutes. Participants will have tests to assess their memory and other mental skills. They will answer questions about their mood and daily life. These tests will take about 40 minutes to complete; they may be done in person or by phone. Participants will give a contact number for someone who can answer questions about the participant s daily routine. These questions may be answered in person or by phone. Participants will be in this study for 5 years. | Alzheimer | À vérifier | À vérifier | United States | À vérifier |
| BNCBackground: \- Alzheimer s disease (AD) is a brain disease that impairs memory, cognitive abilities and the ability to function independently. It is the most common cause of dementia in older people. It is caused by abnormal proteins in the brain that affect how neurons communicate with each other. Researchers are looking for drugs that can slow down the disease or treat its symptoms. One drug, called bisnorcymserine (BNC), may help improve brain function and symptoms in people with AD. BNC is designed to block a chemical that affects how neurons communicate with each other. Researchers want to see how BNC works in healthy older volunteers. Objectives: \- To look at how the body processes bisnorcymserine taken by mouth and how safe it is for healthy older volunteers. Eligibility: \- Healthy volunteers at least 55 years of age. Design: * Participants will be screened with a physical exam, medical history, and blood and urine tests. * Within 3 weeks from the screening visit, participants will come to the National Institute on Aging clinical unit for a 2-night stay. On the morning of the second day, they will take either a BNC capsule or a placebo. They will not know which tablet they are taking. * Blood samples will be collected frequently throughout the second and third days of the study visit. The last blood sample will be collected about 32 hours after taking the study capsule. Participants will have heart function tests and other exams during the visit. Once the tests are done, they will leave the clinical center. * Participants will have a final follow-up visit about 1 week after leaving the clinical center. | Alzheimer | Phase 1 | Traitement symptomatique | United States | À vérifier |
| IbuprofenThe purpose of this study is to test the effect of ibuprofen on the levels of a number of different proteins (called biomarkers) in cerebrospinal fluid (CSF), blood, and urine to see whether ibuprofen can influence certain biomarkers associated with the progression of Alzheimer's Disease. | Alzheimer | Phase 1 | Ralentissement de la progression | United States | À vérifier |
| PsilocybinDescription non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé. | Alzheimer, Cancer, Migraine, Parkinson, Sclérose latérale amyotrophique | Phase 2 | À vérifier | United States | À vérifier |
| PsilocybinDescription non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé. | Sclérose latérale amyotrophique | Phase 1 | À vérifier | United States | À vérifier |
| IbuprofenThe purpose of this study is to test the effect of ibuprofen on the levels of a number of different proteins (called biomarkers) in cerebrospinal fluid (CSF), blood, and urine to see whether ibuprofen can influence certain biomarkers associated with the progression of Alzheimer's Disease. | Alzheimer | Phase 1 | Ralentissement de la progression + Immunomodulation | United States | À vérifier |
| PsilocybinThis study aims to study the feasibility of psilocybin therapy for patients with Amyotropic Lateral Sclerosis (ALS) with depressed mood. The secondary objective is to assess its impact on depression, quality of life, hopelessness, and functional status in this patient population. | Parkinson | Phase 2 | À vérifier | United States | À vérifier |
| Amyloid PET Imaging in the Baltimore Longitudinal Study of AgingBackground: Some people experience cognitive decline as they age. That is, they lose memory, problem-solving, and other mental abilities. Amyloids are groups of proteins that develop in the brain and increase in number as people age. Researchers want to use imaging scans to track amyloids in people s brains over time. Their goal is to find out if any changes are related to cognitive decline or other medical issues. Objective: To learn how amyloids may affect brain structure and function as people age. Eligibility: People aged 55 years and older who are enrolled in the Baltimore Longitudinal Study of Aging. Design: Participants will have imaging scans and other tests every 1 to 4 years, depending on their age. Those 80 and older will be scanned yearly. These scans will be done during regular BLSA visits. The scans will be positron emission tomography and computed tomography (PET CT). Participants will be given fluid through a tube inserted into a vein in their arm. The fluid is a tracer that will cause the amyloids to light up in the images. Then they will lie on a bed with their head inside a PET CT scanner. They will lie still for about 30 minutes. Participants will have tests to assess their memory and other mental skills. They will answer questions about their mood and daily life. These tests will take about 40 minutes to complete; they may be done in person or by phone. Participants will give a contact number for someone who can answer questions about the participant s daily routine. These questions may be answered in person or by phone. Participants will be in this study for 5 years. | Alzheimer | À vérifier | À vérifier | United States | À vérifier |
| PsilocybinThis study aims to study the feasibility of psilocybin therapy for patients with Amyotropic Lateral Sclerosis (ALS) with depressed mood. The secondary objective is to assess its impact on depression, quality of life, hopelessness, and functional status in this patient population. | Alzheimer | Phase 2 | À vérifier | United States | À vérifier |
| BNCBackground: \- Alzheimer s disease (AD) is a brain disease that impairs memory, cognitive abilities and the ability to function independently. It is the most common cause of dementia in older people. It is caused by abnormal proteins in the brain that affect how neurons communicate with each other. Researchers are looking for drugs that can slow down the disease or treat its symptoms. One drug, called bisnorcymserine (BNC), may help improve brain function and symptoms in people with AD. BNC is designed to block a chemical that affects how neurons communicate with each other. Researchers want to see how BNC works in healthy older volunteers. Objectives: \- To look at how the body processes bisnorcymserine taken by mouth and how safe it is for healthy older volunteers. Eligibility: \- Healthy volunteers at least 55 years of age. Design: * Participants will be screened with a physical exam, medical history, and blood and urine tests. * Within 3 weeks from the screening visit, participants will come to the National Institute on Aging clinical unit for a 2-night stay. On the morning of the second day, they will take either a BNC capsule or a placebo. They will not know which tablet they are taking. * Blood samples will be collected frequently throughout the second and third days of the study visit. The last blood sample will be collected about 32 hours after taking the study capsule. Participants will have heart function tests and other exams during the visit. Once the tests are done, they will leave the clinical center. * Participants will have a final follow-up visit about 1 week after leaving the clinical center. | Alzheimer | Phase 1 | Traitement symptomatique | United States | À vérifier |
| PsilocybinThis study aims to study the feasibility of psilocybin therapy for patients with Amyotropic Lateral Sclerosis (ALS) with depressed mood. The secondary objective is to assess its impact on depression, quality of life, hopelessness, and functional status in this patient population. | Migraine | Phase 1 | À vérifier | United States | À vérifier |
| PsilocybinThis study aims to study the feasibility of psilocybin therapy for patients with Amyotropic Lateral Sclerosis (ALS) with depressed mood. The secondary objective is to assess its impact on depression, quality of life, hopelessness, and functional status in this patient population. | Cancer | Phase 2 | À vérifier | United States | À vérifier |
| PsilocybinThis study aims to study the feasibility of psilocybin therapy for patients with Amyotropic Lateral Sclerosis (ALS) with depressed mood. The secondary objective is to assess its impact on depression, quality of life, hopelessness, and functional status in this patient population. | Alzheimer | Phase 1 | À vérifier | United States | À vérifier |
Essais cliniques
9| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Psilocybin | Alzheimer | Phase 1 | NCT04123314 | Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease | RECRUITING |
| Psilocybin | Cancer | Phase 2 | NCT06200155 | Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy | RECRUITING |
| Psilocybin | Migraine | Phase 1 | NCT06464367 | Mechanistic Studies of Psilocybin in Headache Disorders | RECRUITING |
| BNC | Alzheimer | Phase 1 | NCT01747213 | Bisnorcymserine in Healthy Adult Volunteers | COMPLETED |
| Psilocybin | Alzheimer | Phase 2 | NCT07721467 | Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin | RECRUITING |
| Amyloid PET Imaging in the Baltimore Longitudinal Study of Aging | Alzheimer | À vérifier | NCT07099053 | Amyloid PET Imaging in the Baltimore Longitudinal Study of Aging | RECRUITING |
| Psilocybin | Parkinson | Phase 2 | NCT06455293 | PDP2 — Psilocybin Therapy for Depression in Parkinson's Disease | RECRUITING |
| Ibuprofen | Alzheimer | Phase 1 | NCT00239746 | BONSAI: Biomarkers of Nonsteroidal Anti-Inflammatories | UNKNOWN |
| Psilocybin | Sclérose latérale amyotrophique | Phase 1 | NCT06656702 | Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis | RECRUITING |
Publications
28| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Ibuprofen | Discovery of novel ibuprofen-1,3,4-thiadiazole derivatives attenuating ulcerative colitis by regulating MAPK-mediated inflammation and restoring intestinal immune homeostasis. | European journal of medicinal chemistry | ||
| Ibuprofen | Targeting CXCL8 in post-traumatic stress disorder and Alzheimer's disease: insights from cross-disorder molecular analysis. | Annals of medicine | ||
| Ibuprofen | Statement of Retraction: Ibuprofen promotes p75 neurotrophin receptor expression through modifying promoter methylation and N6-methyladenosine-RNA-methylation in human gastric cancer cells. | Bioengineered | ||
| Psilocybin | Psychedelics and autism spectrum disorder: Mechanistic insights, translational evidence and ethical challenges. | Journal of psychiatric research | ||
| Psilocybin | Changes in anxiety, quality of life, and functioning following psilocybin-assisted therapy in veterans with treatment-resistant depression. | Journal of affective disorders | ||
| Psilocybin | Pupil-DLC: An open-source deep learning pipeline for scalable, marker-less tracking of pupil dynamics across conscious and unconscious states. | Journal of neuroscience methods | ||
| Ibuprofen | Polyphenol-Loaded Liposomal Nanocarriers from : A Promising Nutraceutical Delivery System with Enhanced Bioactivity and Safety. | Molecules (Basel, Switzerland) | ||
| Ibuprofen | Acute Pain Management in Children: A Systematic Review and GRADE-Based Recommendations. | Journal of clinical medicine | ||
| Psilocybin | Psychedelics and astrocytes: a hypothesis-driven perspective on neuro-glial integration, network plasticity, and neuroimmune reprogramming. | Molecular psychiatry | ||
| Psilocybin | The mechanism debate in psilocybin therapy for depression. | EBioMedicine | ||
| Ibuprofen | Crosslinked gelatin pastilles prepared via maillard reaction as oral dosage form of ionic liquid pharmaceuticals. | International journal of biological macromolecules | ||
| Ibuprofen | Adaptive genetic trade-offs govern the enantioselective degradation and horizontal transfer of ibuprofen catabolic genes. | Journal of hazardous materials | ||
| Psilocybin | Psilocybin produces amplified acute responses and sex-specific long-term increases in sensorimotor gating in the mGlu5 knockout mouse model of schizophrenia. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology | ||
| Psilocybin | Psilocybin as serotonergic therapy in epilepsy: Narrative review of potentials and limitations. | British journal of clinical pharmacology | ||
| Ibuprofen | Metabolomic insights into migraine: mechanisms and biomarkers from in vivo and clinical studies. | Metabolic brain disease | ||
| Ibuprofen | Pulpotomy for an Immature Permanent Tooth With Symptomatic Irreversible Pulpitis Using Cold Ceramic. | Case reports in dentistry | ||
| Psilocybin | Silence is golden: Documenting the speech production of participants and support providers in psilocybin administration sessions for the treatment of post-traumatic stress disorder. | Journal of psychopharmacology (Oxford, England) | ||
| Psilocybin | Psilocybin selectively rescues cognitive flexibility impairments caused by aberrant prefrontal error signaling. | bioRxiv : the preprint server for biology | ||
| Psilocybin | Acute Hallucinogen Intoxication Following Ingestion of a Commercially Available Mushroom Extract Product: A Case Report. | Cureus | ||
| Ibuprofen | Management of moderate pain after orthopaedic surgery: A multiregional expert consensus model for postoperative and discharge protocol development. | Journal of experimental orthopaedics | ||
| Psilocybin | Psilocybin-induced behavioral and cellular effects. | Journal of neurogenetics | ||
| Psilocybin | Acceptability and safety of two sequential doses of psilocybin in bipolar II depression: protocol for an open-label single-arm feasibility study. | BMJ open | ||
| Ibuprofen | Ketamine-induced cystitis: Lessons from a case of recreational use. | Journal of the American Pharmacists Association : JAPhA | ||
| Ibuprofen | Ge-Gen Decoction Modulates the HSP90/AKT Signaling Pathway and the NLRP3 Inflammasome to Alleviate Primary Dysmenorrhea. | Journal of pain research | ||
| Psilocybin | Psychedelics produce enduring enhancement of reward responsiveness in male rats. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology | ||
| Psilocybin | Psilocybin-assisted therapy in treatment-resistant depression: rapid remission, uncertain durability, and the next phase of clinical evidence. | Annals of medicine and surgery (2012) | ||
| Psilocybin | α-Adrenergic receptor modulates 5-HT-mediated behavioral effects of MDMA and psilocybin in mice. | Molecular psychiatry | ||
| Psilocybin | CSF galanin and noradrenaline downregulation by psilocybin therapy in major depressive disorder. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology |